Global Leading Market Research Publisher QYResearch announces the release of its latest report *”Oncology Clinical Imaging Solutions – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″*.
For pharmaceutical companies, clinical research organizations (CROs), and oncology research institutes, the challenge of accurately assessing cancer stage, treatment response, and disease progression is fundamental to drug development and patient care. Traditional imaging interpretation is subjective, variable across readers and sites, and difficult to standardize across multi-center clinical trials. The strategic solution lies in oncology clinical imaging solutions—specialized services that provide centralized, standardized, and expert interpretation of medical imaging modalities including CT, MRI, MRA, and PET/CT, enabling referring physicians and researchers to detect, diagnose, and monitor cancer with greater consistency and confidence. This report delivers strategic intelligence on market size, service models, and application drivers for pharmaceutical and healthcare decision-makers.
According to QYResearch data, the global market for oncology clinical imaging solutions was estimated to be worth USD 733 million in 2024 and is forecast to reach USD 1,231 million by 2031, growing at a compound annual growth rate (CAGR) of 7.8% during the forecast period 2025-2031.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/3499943/oncology-clinical-imaging-solutions
Market Definition & Core Value Proposition
Medical imaging has become integral to cancer care, assessing the stage and location of cancerous tumors. By utilizing powerful imaging modalities including CT (Computed Tomography), MRI (Magnetic Resonance Imaging), MRA (Magnetic Resonance Angiography), and PET/CT (Positron Emission Tomography/Computed Tomography), oncology imaging radiologists are able to assist referring physicians in the detection and diagnosis of cancer.
Oncology clinical imaging solutions encompass specialized services that support cancer clinical trials and oncology practice through standardized imaging acquisition, centralized image management, expert blinded reads, quantitative image analysis, and regulatory-compliant reporting. These solutions address critical challenges in oncology drug development:
- Standardization: Ensuring imaging protocols are consistent across hundreds of clinical trial sites globally, enabling comparability of data.
- Objectivity: Blinded independent central reviews (BICR) eliminate reader bias inherent in local site reads.
- Quantification: Advanced image analysis (tumor volumetrics, RECIST 1.1, iRECIST, modified RECIST for immunotherapy) provides objective endpoints for regulatory approval.
- Compliance: FDA and EMA require independent imaging review for registration trials in solid tumors (response assessment, progression-free survival endpoints).
Key imaging modalities used in oncology clinical imaging solutions:
- CT (Computed Tomography) : The standard for anatomic tumor measurement (size, location, morphology). Used for RECIST 1.1 (Response Evaluation Criteria in Solid Tumors) assessments in most solid tumor trials.
- MRI (Magnetic Resonance Imaging) : Superior soft tissue contrast for brain tumors, liver metastases, prostate cancer, and musculoskeletal tumors. Used when CT lacks sufficient contrast.
- PET/CT (Positron Emission Tomography/CT) : Combines functional (metabolic activity, using F-18 FDG tracer) and anatomic imaging. Used for lymphoma, lung cancer, esophageal cancer, and treatment response assessment (PERCIST criteria).
- MRA (Magnetic Resonance Angiography) : Visualizes blood vessels; used for tumor vascularity assessment and interventional planning.
A typical user case (pharmaceutical clinical trial): In December 2025, a global pharmaceutical company initiated a Phase 3 registration trial for a novel immunotherapy in non-small cell lung cancer (NSCLC). The trial enrolled 800 patients across 150 sites in 25 countries. An oncology clinical imaging solution provider was engaged to provide centralized imaging services including site training (standardizing CT acquisition protocols), image quality control (ensuring diagnostic quality), blinded independent central review (BICR) of baseline, on-treatment, and follow-up scans, and RECIST 1.1 response assessments. The central review data were used as the primary endpoint for FDA submission. The provider completed reads within 5 business days of image receipt, maintaining trial timelines and data integrity.
A typical user case (research institute): In January 2026, a National Cancer Institute (NCI)-designated cancer center partnered with an imaging solution provider to support an investigator-initiated trial of neoadjuvant therapy in breast cancer. The provider performed quantitative MRI analysis (apparent diffusion coefficient mapping, tumor volume change) to assess early treatment response after the first cycle, enabling adaptive trial design (patients with poor response switched to alternative therapy).
Key Industry Characteristics Driving Market Growth
1. Service Type Segmentation: Central Imaging Service Dominates, In-House Growing
The report segments the market by imaging service delivery model:
- Central Imaging Service (Approx. 60–65% of 2024 revenue, largest segment) : Outsourced, centralized imaging solutions provided by specialized imaging CROs (Clario, ICON, Parexel, Imaging Endpoints, Intrinsic Imaging). Central imaging services include site training and qualification (ensuring protocol-compliant acquisition), image receipt and quality control, de-identification and pseudonymization, blinded independent central review (BICR), quantitative image analysis (tumor measurements, volumetric analysis), and regulatory-compliant reporting (electronic case report forms, data transfer to clinical database). Central imaging is the standard for registration trials requiring independent response assessment. Growth is driven by increasing trial complexity (adaptive designs, combination therapies, novel response criteria), regulatory requirements (FDA guidance requires BICR for solid tumor registration trials), and sponsor preference for outsourcing non-core activities.
- In-House Imaging Service (Approx. 35–40% of revenue, fastest-growing segment at 9–10% CAGR) : Imaging solutions provided by the pharmaceutical company’s internal imaging department or academic medical center’s radiology department. In-house services offer greater control, faster turnaround for internal decision-making (Phase 1/2 trials, go/no-go decisions), and lower cost per patient (no CRO markup). However, in-house services lack the scale, standardization, and regulatory expertise of specialized imaging CROs. The in-house segment is growing as larger pharmaceutical companies build internal imaging capabilities for early-phase trials, reserving central imaging for registration trials.
Exclusive industry insight: The distinction between central imaging for registration trials and in-house imaging for early development is critical for market segmentation. Registration trials require independent central review (FDA/EMA mandate for solid tumor response endpoints), specialized CROs with regulatory expertise, and documented reader qualification and inter-reader reliability. Early-phase trials (Phase 1, proof-of-concept, Phase 2a) may use in-house imaging or lighter-touch central imaging (no independent review, local reads with central archiving) to reduce costs and accelerate timelines. The market is shifting toward hybrid models: in-house imaging for rapid internal decisions, central imaging for registration endpoints, with seamless data transfer between systems.
2. Application Segmentation: Pharmaceutical Companies Largest, Research Institutes Fastest Growing
- Pharmaceutical Companies (Approx. 75–80% of 2024 revenue, largest segment) : Sponsors of oncology clinical trials (Phase 1-4) requiring imaging endpoints for regulatory submission. Pharmaceutical companies engage imaging solution providers for site training and qualification, image management, blinded independent central review (BICR), and quantitative image analysis. The pharmaceutical segment is driven by increasing oncology R&D spending (global oncology drug development pipeline exceeds 7,000 active compounds), regulatory requirements for independent imaging review (FDA guidance for solid tumor trials), and complexity of modern trials (adaptive designs, novel response criteria like iRECIST for immunotherapy, combination regimens).
A typical user case (pharmaceutical company): In February 2026, a mid-sized biotech company with no internal imaging capabilities outsourced all imaging aspects of its Phase 2 ovarian cancer trial to a central imaging CRO. The CRO provided site training (CT and MRI protocols), image quality control, BICR for RECIST assessments, and data transfer to the clinical database. The biotech estimated that outsourcing saved 18 months of internal infrastructure development and USD 2 million in capital expenses.
- Research Institutes (Approx. 15–20% of revenue, fastest-growing segment at 9–10% CAGR) : Academic medical centers, National Cancer Institute (NCI) cooperative groups, and independent research organizations conducting investigator-initiated trials, correlative science studies, and imaging biomarker development. Research institutes require imaging solutions for quantitative image analysis (radiomics, texture analysis, machine learning models), longitudinal imaging studies (natural history, screening), and multi-center academic trials (often with less stringent regulatory requirements than pharmaceutical registration trials). The research institute segment is growing due to increasing NIH/NCI funding for imaging biomarkers, open science initiatives (sharing de-identified imaging data), and academic-industry partnerships.
- Others (Approx. 5% of revenue) : Includes government agencies (FDA imaging review, NCI imaging programs), contract research organizations (CROs) integrating imaging services into broader clinical trial offerings, and diagnostic imaging providers expanding into clinical trial support.
3. Regional Dynamics: North America Leads, Europe and Asia-Pacific Follow
North America accounts for approximately 45–50% of global oncology clinical imaging solution revenue, driven by concentration of pharmaceutical R&D spending (US-based companies account for over 45% of global oncology drug development), regulatory leadership (FDA guidance mandating BICR for solid tumor registration trials), and presence of major imaging CROs (Clario, ICON, Parexel, Imaging Endpoints, Intrinsic Imaging, BioTelemetry/Philips).
Europe accounts for approximately 25–30% of revenue, led by the United Kingdom, Germany, France, and Switzerland (home to major pharmaceutical companies and CROs). European Medicines Agency (EMA) requirements for independent imaging review align with FDA, driving demand.
Asia-Pacific is the fastest-growing region (CAGR 9–10%), driven by increasing oncology clinical trial activity in China (over 1,500 active oncology trials as of 2025, spurred by regulatory reforms and NMPA requirements for local data), Japan (PMDA requirements for imaging endpoints), South Korea, and Australia (early-phase trial hub). Local imaging CROs are emerging, but global CROs dominate large multi-regional trials.
Key Players & Competitive Landscape (2025–2026 Updates)
The oncology clinical imaging solution market features a specialized competitive landscape with imaging-focused CROs and broader clinical trial service providers. Leading players include Clario (US, imaging and cardiac safety), ICON (Ireland, full-service CRO with imaging division), McLaren (UK, imaging CRO), Parexel (US, full-service CRO with imaging division), BioTelemetry (Philips) (US, cardiac and imaging services, acquired by Philips), Imaging Endpoints (US, imaging CRO specializing in oncology), Radiant Sage (US, imaging software and services), Micron, Inc. (US), Intrinsic Imaging (WCG) (US, acquired by WCG), and Banook Medical (France, cardiac and imaging CRO).
Recent strategic developments (last 6 months):
- Clario (January 2026) launched its AI-assisted tumor volumetry platform for RECIST assessments, reducing reader time by 40% while maintaining inter-reader agreement (kappa >0.85), addressing the growing challenge of reader shortage.
- ICON (December 2025) announced a strategic partnership with a cloud imaging vendor to provide fully integrated imaging and clinical data management, enabling real-time data reconciliation and faster database locks for oncology trials.
- Imaging Endpoints (February 2026) received FDA qualification for its quantitative PET/CT analysis methodology (PERCIST) for immunotherapy response assessment, enabling use as a secondary endpoint in registration trials.
- Intrinsic Imaging (WCG) (March 2026) expanded its global reader network to 150 board-certified radiologists across 12 countries, enabling 24/7 blinded independent central review for global trials.
- BioTelemetry (Philips) (November 2025) integrated its imaging solutions with Philips’ PACS (Picture Archiving and Communication System), enabling seamless transfer of clinical trial images from hospital radiology departments to central imaging CROs.
Technical Challenges & Innovation Frontiers
Current technical hurdles remain:
- Inter-reader variability: Even with RECIST guidelines, different radiologists measuring the same tumor may produce different results (variability up to 20% for small target lesions). Centralized training, reader qualification exams, and AI-assisted measurement tools reduce but do not eliminate variability.
- Site qualification and compliance: Ensuring 150+ global trial sites follow identical imaging protocols (slice thickness, contrast timing, patient positioning, scanner manufacturer/model) is challenging. Imaging CROs provide site training manuals, educational webinars, and ongoing image quality monitoring. Non-compliant images must be repeated, delaying trial timelines.
- Regulatory requirements for imaging biomarkers: FDA qualification of novel imaging biomarkers (e.g., total lesion glycolysis from PET/CT, apparent diffusion coefficient from MRI) requires extensive validation (analytical, clinical, and regulatory). Most trials rely on conventional RECIST despite its limitations (does not capture tumor heterogeneity, metabolic response, or pseudo-progression in immunotherapy).
- Data volume and transfer: Oncology trials generate large imaging datasets (1-5 GB per patient per time point; 500-2,500 GB for a 500-patient trial with 5 time points). Transferring images from sites to central imaging CROs requires secure, high-bandwidth infrastructure. Cloud-based solutions (vendor-neutral archives, direct site upload) are replacing physical media (DVDs, hard drives).
Exclusive industry insight: The distinction between anatomic imaging (CT, MRI) and functional/molecular imaging (PET/CT, PET/MRI) is significant for oncology clinical trials. Anatomic imaging remains the regulatory standard for response assessment (RECIST). Functional imaging offers earlier detection of treatment response (metabolic changes precede size changes by days to weeks) and better assessment of novel therapies (immunotherapy, targeted therapy) but lacks regulatory qualification for primary endpoints. The market is shifting toward hybrid solutions (anatomic + functional imaging, quantitative imaging biomarkers) as regulatory pathways for imaging biomarkers mature.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
